Tom Tamberrino Joins Profound Medical as Chief Commercial Officer

Profound Medical Corp. has appointed Tom Tamberrino as its new chief commercial officer, succeeding Abbey Goodman, who will lead the company’s strategic partnerships and report to CEO/Chairman Arun Menawat, Ph.D.

“Over the past several months, Abbey has helped lead the charge as we have begun building closer relationships with MR and other medical technology companies to help create a total diagnostic and interventional MRI solution to support the Modern Treatment Pathway that allows for more accurate and precise prostate disease diagnosis, treatment with the TULSA Procedure, and post-treatment follow-up,” Dr. Menawat said. “I am excited that Abbey has accepted this newly created and important role, and look forward to her continuing contributions to realizing this shared MR-centric vision.”

Tamberrino has an accomplished history of sales and marketing leadership, business development, executive management, and entrepreneurial success, most of which he gained in the U.S. healthcare industry.

Tamberrino was vice president, Sales and Marketing, at NOVADAQ Technologies Inc. before accepting a job outside of the medical technology industry. He was recruited to join Profound Medical by Dr. Menawat, the former chairman, president, and CEO of NOVADAQ during Tamberrino’s tenure there.

“This is actually the second time I have personally recruited Tom to build and manage the sales organizations of companies led by me as CEO—first from LifeCell to NOVADAQ and now to Profound,” Dr. Menawat noted. “The permanent CPT Category 1 codes for TULSA going into effect at the beginning of 2025 represent an anticipated major inflection point for our business. Now is the perfect time to bring in a sales and marketing executive that I have worked with closely in the past; and one who has earned my trust, respect and most importantly, confidence, in the process. I am honored and excited to welcome Tom to Profound.”

While at NOVADAQ, Tamberrino helped establish the company as the market leader in near infrared fluorescence imaging for visualizing blood flow and tissue perfusion, before, during, and after surgical procedures. He built a direct U.S. sales and marketing organization driving an annual revenue run rate of approximately $27 million at the end of 2012, to more than $82 million in annualized revenues when Stryker Corp. purchased NOVADAQ in 2017 for approximately $701 million. Tamberrino remained with NOVADAQ until 2018 to assist with the company’s integration into the Stryker organization.

Earlier in his career, Tamborrino held progressive sales management positions with LifeCell Corporation, most recently serving as Area Director. He managed a 50-person sales team in the northeastern United States and Canada that marketed LifeCell’s regenerative tissue matrices alongside NOVADAQ’s intraoperative perfusion assessment technology for complex trauma, cancer, and general surgery cases to colorectal, general, plastic, transplant, and trauma surgeons.

Tamberrino earned a bachelor of science degree in marketing, and a minor in psychology from Georgetown University, and an MBA from Emory University.

“As naturally inclined as I was to be warmly receptive to Arun’s overtures to join him at Profound, I wanted to be certain that I would be able to hit the ground running,” Tamberrino stated. “And, like many men that I had spoken to, I naturally wondered why any prostate disease patient who was presented with an informed choice of available treatment options would not choose TULSA given its ability to effectively, safely, and efficiently treat an unrivaled variety of prostate cancer and/or benign prostatic hyperplasia (BPH) patients. So, I did a lot of diligence. As a result, I am convinced that widespread adoption of TULSA will be driven mostly by increasing patient and physician awareness, and by ensuring TULSA can be readily accessed in the most suitable settings, including hospitals, ASCs and private practice offices/facilities. Importantly, with reimbursement now on the horizon, I was not able to identify any remaining major obstacles to widespread adoption of TULSA-PRO. I am looking forward to working with Arun, Abbey, and the rest of the Profound team to maximize the tremendous opportunity we see ahead.”

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, could potentially become a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. TULSA employs real-time MR guidance for pixel-by-pixel precision to preserve prostate disease patients’ urinary continence and sexual function, while killing the targeted prostate tissue through a precise sound absorption technology that gently heats it to kill temperature (55°-57°C). TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration.

Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for treating uterine fibroids and palliative pain associated with bone metastases. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive uterine fibroid treatment and has FDA approval under a Humanitarian Device Exemption for treating osteoid osteoma. The company is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has shown promise, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.